- Welcome to the New Mexico Chapter of the American College of Cardiology
- Welcome to the New Mexico Chapter of the American College of Cardiology
ACC Live Courses For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings |
Latest in Cardiology from ACC.org
- ACC-Hosted UN Side Events Focus on Opportunities to Address Global Burden of NCDsWith the fourth High-level United Nations General Assembly (UNGA) meeting taking place in New York the week of Sept. 22, the ACC hosted two separate side events tied into the overall theme of "Equity and Integration: Transforming Lives and Livelihoods Through Leadership and Action on Noncommunicable Diseases (NCDs) and the Promotion of Mental Health and […]
- New Global Burden of CVD Report Shows Wide Variation Among CountriesCardiovascular disease remains the leading cause of disease burden, causing one in three deaths worldwide, according to the latest Global Burden of Disease study report published Sept. 24 in JACC and presented during a special side event as part of the 80th Session of the United Nations General Assembly in New York.
- OASIS 4: Significant Weight Loss With Oral Semaglutide Comparable With High-Dose, SC VersionsOral semaglutide 25 mg once daily was associated with significant weight loss vs. placebo, comparable with that seen with the 50 mg oral dose and with the subcutaneous (SC) injectable version of the drug, according to new results from the phase 3 OASIS 4 trial, published Sept. 17 in NEJM.
- Metoprolol Versus Aficamten in Patients With Left Ventricular Outflow Tract Obstruction on Exercise Capacity in HCMThe MAPLE-HCM trial showed that, among patients with symptomatic obstructive HCM, aficamten monotherapy was superior to metoprolol monotherapy in improving peak oxygen uptake and hemodynamics, and decreasing symptoms.
- A Study of Mavacamten in Nonobstructive Hypertrophic CardiomyopathyAmong patients with nonobstructive HCM in the ODYSSEY-HCM trial, mavacamten failed to significantly improve peak oxygen uptake or improve health status compared with placebo.